Autor: "Zile MR" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: Influence of study discontinuation during the run-in period on the estimated efficacy of sacubitril/valsartan in the PARAGON-HF trial.
Autorzy:: Suzuki K; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Claggett B; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Minamisawa M; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Packer M; Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX, USA.
Zile MR; Ralph H. Johnson Department of Veterans Affairs Medical Center, Charleston, SC, USA.
Pfeffer MA; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Chiang LM; Novartis Pharmaceuticals, East Hanover, NJ, USA.
Lefkowitz M; Novartis Pharmaceuticals, East Hanover, NJ, USA.
McMurray JJV; BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Solomon SD; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Desai AS; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.; Pokaż więcej
Źródło:: European journal of heart failure [Eur J Heart Fail] 2021 Dec; Vol. 23 (12), pp. 2085-2090. Date of Electronic Publication: 2021 Jul 01.
Typ publikacji:: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:: Angiotensin Receptor Antagonists*/adverse effects
Heart Failure*
Aminobutyrates/pharmacology ; Aminobutyrates/therapeutic use ; Biphenyl Compounds ; Drug Combinations ; Humans ; Stroke Volume/physiology ; Tetrazoles/pharmacology ; Tetrazoles/therapeutic use ; Valsartan

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: Liver function and prognosis, and influence of sacubitril/valsartan in patients with heart failure with reduced ejection fraction.
Autorzy:: Suzuki K; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Claggett B; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Minamisawa M; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Packer M; Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX, USA.
Zile MR; Medical University of South Carolina and Ralph H. Johnson Department of Veterans Affairs Medical Center, Charleston, SC, USA.
Rouleau J; University of Montreal, Montreal, Quebec, Canada.
Swedberg K; University of Gothenburg, Gothenburg, Sweden.
Lefkowitz M; Novartis, East Hanover, NJ, USA.
Shi V; Novartis, East Hanover, NJ, USA.
McMurray JJV; University of Glasgow, Glasgow, UK.
Zucker SD; Division of Gastroenterology, Hepatology, and Endoscopy, Brigham and Women's Hospital, Boston, MA, USA.
Solomon SD; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.; Pokaż więcej
Źródło:: European journal of heart failure [Eur J Heart Fail] 2020 Sep; Vol. 22 (9), pp. 1662-1671. Date of Electronic Publication: 2020 May 14.
Typ publikacji:: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:: Heart Failure*/drug therapy
Angiotensin Receptor Antagonists/*therapeutic use
Aminobutyrates ; Biphenyl Compounds ; Drug Combinations ; Humans ; Liver ; Prognosis ; Stroke Volume ; Valsartan

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 3.

Tytuł:: Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction.
Autorzy:: Cannon JA; BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Shen L; BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Jhund PS; BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Kristensen SL; Rigshospitalet Copenhagen University Hospital, Copenhagen.
Køber L; Rigshospitalet Copenhagen University Hospital, Copenhagen.
Chen F; Novartis Pharmaceutical Corporation, East Hanover, NJ, USA.
Gong J; Novartis Pharmaceutical Corporation, East Hanover, NJ, USA.
Lefkowitz MP; Novartis Pharmaceutical Corporation, East Hanover, NJ, USA.
Rouleau JL; Institut de Cardiologie, Université de Montréal, Montréal, Canada.
Shi VC; Novartis Pharmaceutical Corporation, East Hanover, NJ, USA.
Swedberg K; Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden and National Heart and Lung Institute, Imperial College, London.
Zile MR; Medical University of South Carolina and RHJ Department of Veterans Administration Medical Center, Charleston, SC, USA.
Solomon SD; Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Packer M; Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX, USA.
McMurray JJ; BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.; Pokaż więcej
Corporate Authors:: PARADIGM-HF Investigators and Committees
Źródło:: European journal of heart failure [Eur J Heart Fail] 2017 Jan; Vol. 19 (1), pp. 129-137. Date of Electronic Publication: 2016 Nov 20.
Typ publikacji:: Journal Article; Randomized Controlled Trial
MeSH Terms:: Aminobutyrates/*therapeutic use
Angiotensin Receptor Antagonists/*therapeutic use
Angiotensin-Converting Enzyme Inhibitors/*therapeutic use
Dementia/*epidemiology
Enalapril/*therapeutic use
Heart Failure/*drug therapy
Tetrazoles/*therapeutic use
Aged ; Amnesia/epidemiology ; Biphenyl Compounds ; Confusion/epidemiology ; Delirium/epidemiology ; Disorders of Excessive Somnolence/epidemiology ; Drug Combinations ; Female ; Heart Failure/physiopathology ; Humans ; Male ; Middle Aged ; Neprilysin/antagonists & inhibitors ; Proportional Hazards Models ; Stroke Volume ; Valsartan

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 4.

Tytuł:: Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial.
Autorzy:: Vardeny O; Pharmacy Practice Division, University of Wisconsin School of Pharmacy, Madison, WI, USA.
Claggett B; Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA.
Packer M; Division of Cardiology; Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, USA.
Zile MR; Medical University of South Carolina and Ralph H. Johnston Veterans Administration Medical Center, Charleston, NC, USA.
Rouleau J; Institut de Cardiologie de Montreal, Université de Montréal, Montreal, Canada.
Swedberg K; University of Gothenburg, Gothenburg, Sweden and National Heart and Lung Institute, Imperial College, London, UK.
Teerlink JR; University of California-San Francisco and San Francisco Veterans Affairs Medical Center, San Francisco, CA, USA.
Desai AS; Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA.
Lefkowitz M; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
Shi V; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
McMurray JJ; British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Solomon SD; Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA. .; Pokaż więcej
Corporate Authors:: Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Investigators
Źródło:: European journal of heart failure [Eur J Heart Fail] 2016 Oct; Vol. 18 (10), pp. 1228-1234. Date of Electronic Publication: 2016 Jun 10.
Typ publikacji:: Journal Article; Randomized Controlled Trial
MeSH Terms:: Aminobutyrates/*administration & dosage
Angiotensin Receptor Antagonists/*administration & dosage
Enalapril/*administration & dosage
Heart Failure/*drug therapy
Tetrazoles/*administration & dosage
Aged ; Biphenyl Compounds ; Dose-Response Relationship, Drug ; Double-Blind Method ; Drug Combinations ; Female ; Heart Failure/physiopathology ; Humans ; Male ; Middle Aged ; Stroke Volume/drug effects ; Valsartan